Technology
MPI is a pharmacodiagnostic company with proprietary pivotal technology (DNA microarray, qPCR based) which is universally applicable to any drug and any disease to determine Drug Response Prediction (DRP). Based on a small tumour sample or blood sample, MPI’s Drug Response Predictor™ it predicts which existing chemotherapeutic drug the tumour is most sensitive to. The tumour sample is analyzed on a DNA microarray and the gene expression profile is processed by MPI's proprietary patented software. The technology has been proven in several retrospective validations on a large number of patients, diseases, drugs, and biologics.
Value Proposition
It has become apparent that most chemotherapeutic drugs on the market have varied efficacy with varying genetic profiles. This poses a challenge for both the treatment with and the development of these drugs. MPI's technology will allow developers of chemotherapeutic drugs to speed up drug development by providing a genetic profile of the most relevant patients for the drug to be tested. This will save significant amounts in development cost as well as increase the possibility of success.
Additionally oncologists will be able to use MPI's technology as a guide for selecting the most efficient chemotherapeutic drug or drug combinations for a specific patient.
Additional Information